Beta Thalassemia Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Ionis Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Silence Therapeutics plc, Phoenicia Biosciences, Shanghai BDgene

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Beta Thalassemia pipeline constitutes 22+ key companies continuously working towards developing 22+ Beta Thalassemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Beta Thalassemia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Beta Thalassemia Market.

The Beta Thalassemia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Beta Thalassemia Pipeline Report: https://www.delveinsight.com/sample-request/beta-thalassemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Beta Thalassemia treatment therapies with a considerable amount of success over the years.
• Beta Thalassemia companies working in the treatment market are Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others, are developing therapies for the Beta Thalassemia treatment
• Emerging Beta Thalassemia therapies in the different phases of clinical trials are- PYRUKYND (mitapivat), CTX001, SP-420, EDIT-301, dimethylbutyrate, ACE-536, Luspatercept, Bitopertin, Deferitrin (GT56-252), ICL670, Emeramide, SP-420, Luspatercept, DST-0509, Mitapivat, SPD602, and others are expected to have a significant impact on the Beta Thalassemia market in the coming years.
• In September 2023, Pharmacosmos launched a Phase II trial of SP-420 in patients with transfusion-dependent beta-thalassemia.
• In June 2023, The FDA has accepted the Biologics License Application (BLA) for exagamglogene autotemcel (exa-cel) for treating transfusion-dependent beta thalassemia (TDT). The target action date under the Prescription Drug User Fee Act (PDUFA) for TDT is set for March 30, 2024.

Beta Thalassemia Overview
Beta thalassemia is a genetic blood disorder that reduces the production of hemoglobin, a protein in red blood cells that carries oxygen throughout the body. It results from mutations in the HBB gene, which provides instructions for making the beta-globin subunit of hemoglobin. This disorder leads to a deficiency in the beta-globin chains, causing the red blood cells to become malformed and break down prematurely, leading to anemia.

Get a Free Sample PDF Report to know more about Beta Thalassemia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/beta-thalassemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Beta Thalassemia Drugs Under Different Phases of Clinical Development Include:
• PYRUKYND (mitapivat): Agios Pharmaceuticals
• CTX001: Vertex Pharmaceuticals
• SP-420: Pharmacosmos
• EDIT-301: Editas Medicine
• dimethylbutyrate: HemaQuest Pharmaceuticals
• ACE-536: Acceleron Pharma
• Luspatercept: Bristol-Myers Squibb
• Bitopertin: Hoffmann-La Roche
• Deferitrin (GT56-252): Sanofi
• ICL670: Novartis
• Emeramide: EmeraMed
• SP-420: Pharmacosmos A/S
• Luspatercept: Celgene
• DST-0509: DisperSol Technologies, LLC
• Mitapivat: Agios Pharmaceuticals
• SPD602: Shire

Beta Thalassemia Route of Administration
Beta Thalassemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Beta Thalassemia Molecule Type
Beta Thalassemia Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Beta Thalassemia Pipeline Therapeutics Assessment
• Beta Thalassemia Assessment by Product Type
• Beta Thalassemia By Stage and Product Type
• Beta Thalassemia Assessment by Route of Administration
• Beta Thalassemia By Stage and Route of Administration
• Beta Thalassemia Assessment by Molecule Type
• Beta Thalassemia by Stage and Molecule Type

DelveInsight's Beta Thalassemia Report covers around 22+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Beta Thalassemia product details are provided in the report. Download the Beta Thalassemia pipeline report to learn more about the emerging Beta Thalassemia therapies at:
https://www.delveinsight.com/sample-request/beta-thalassemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Beta Thalassemia Therapeutics Market include:
Key companies developing therapies for Beta Thalassemia are - Ionis Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Silence Therapeutics plc, Phoenicia Biosciences, Shanghai BDgene, Beam Therapeutics, EmeraMed, CRISPR Therapeutics, CSL Vifor, EdiGene (GuangZhou) Inc., Regenacy Pharmaceuticals, Editas Medicine, Fulcrum Therapeutics, Allife Medical Science and Technology, Global Blood Therapeutics, Inc, Orchard Therapeutics, Acceleron Pharma, Disc Medicine, BRL Medicine, Celgene, and others.

Beta Thalassemia Pipeline Analysis:
The Beta Thalassemia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Beta Thalassemia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Beta Thalassemia Treatment.
• Beta Thalassemia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Beta Thalassemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Beta Thalassemia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Beta Thalassemia drugs and therapies-
https://www.delveinsight.com/sample-request/beta-thalassemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Beta Thalassemia Pipeline Market Strengths
• Strong pipeline activity with potential Phase III and phase II emerging therapies.
• Increasing prevalence and awareness of beta thalassemia

Beta Thalassemia Pipeline Market Opportunities
• Lack of any curative treatment options despite the launch of gene therapies which are subject to patient outcome assessment
• Improved national blood policies
• Advancement in genetic engineering because gene therapy has been hypothesized to serve as an effective cure for monogenic blood disorders for several decades

Scope of Beta Thalassemia Pipeline Drug Insight
• Coverage: Global
• Key Beta Thalassemia Companies: Agios Pharmaceuticals, Vertex Pharmaceuticals, Pharmacosmos, Editas Medicine, HemaQuest Pharmaceuticals, Acceleron Pharma, Bristol-Myers Squibb, Hoffmann-La Roche, Sanofi, Novartis, EmeraMed, Pharmacosmos A/S, Celgene, DisperSol Technologies, LLC, Agios Pharmaceuticals, Shire, and others
• Key Beta Thalassemia Therapies: PYRUKYND (mitapivat), CTX001, SP-420, EDIT-301, dimethylbutyrate, ACE-536, Luspatercept, Bitopertin, Deferitrin (GT56-252), ICL670, Emeramide, SP-420, Luspatercept, DST-0509, Mitapivat, SPD602, and others
• Beta Thalassemia Therapeutic Assessment: Beta Thalassemia current marketed and Beta Thalassemia emerging therapies
• Beta Thalassemia Market Dynamics: Beta Thalassemia market drivers and Beta Thalassemia market barriers

Request for Sample PDF Report for Beta Thalassemia Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/beta-thalassemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Beta Thalassemia Report Introduction
2. Beta Thalassemia Executive Summary
3. Beta Thalassemia Overview
4. Beta Thalassemia- Analytical Perspective In-depth Commercial Assessment
5. Beta Thalassemia Pipeline Therapeutics
6. Beta Thalassemia Late Stage Products (Phase II/III)
7. Beta Thalassemia Mid Stage Products (Phase II)
8. Beta Thalassemia Early Stage Products (Phase I)
9. Beta Thalassemia Preclinical Stage Products
10. Beta Thalassemia Therapeutics Assessment
11. Beta Thalassemia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Beta Thalassemia Key Companies
14. Beta Thalassemia Key Products
15. Beta Thalassemia Unmet Needs
16 . Beta Thalassemia Market Drivers and Barriers
17. Beta Thalassemia Future Perspectives and Conclusion
18. Beta Thalassemia Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Beta Thalassemia Market https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Beta Thalassemia Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Beta Thalassemia Epidemiology https://www.delveinsight.com/report-store/beta-thalassemia-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Beta Thalassemia Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.